{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T15:58:48Z","timestamp":1722095928937},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,11]]},"DOI":"10.7759\/cureus.21126","type":"journal-article","created":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T20:15:21Z","timestamp":1641932121000},"source":"Crossref","is-referenced-by-count":0,"title":["Adalimumab-Induced Erythema Multiforme in a Patient With Rheumatoid Arthritis: A Case Report"],"prefix":"10.7759","author":[{"given":"Jinan Q","family":"Mohammed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zainab","family":"Mahmmod","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulsatar J","family":"Mathkhor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxs047","article-title":"Targeting TNF receptors in rheumatoid arthritis","volume":"24","author":"Bl\u00fcml S","year":"2012","unstructured":"Bl\u00fcml S, Scheinecker C, Smolen JS, Redlich K. Targeting TNF receptors in rheumatoid arthritis. Int Immunol. 2012, 24:275-81. 10.1093\/intimm\/dxs047","journal-title":"Int Immunol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s10354-015-0344-y","article-title":"Anti-TNF in rheumatoid arthritis: an overview","volume":"165","author":"Radner H","year":"2015","unstructured":"Radner H, Aletaha D. Anti-TNF in rheumatoid arthritis: an overview. Wien Med Wochenschr. 2015, 165:3-9. 10.1007\/s10354-015-0344-y","journal-title":"Wien Med Wochenschr"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.746396","article-title":"Risk of adverse events after anti-TNF treatment for inflammatory rheumatological disease. A meta-analysis","volume":"12","author":"Li J","year":"2021","unstructured":"Li J, Zhang Z, Wu X, Zhou J, Meng D, Zhu P. Risk of adverse events after anti-TNF treatment for inflammatory rheumatological disease. A meta-analysis. Front Pharmacol. 2021, 12:746396. 10.3389\/fphar.2021.746396","journal-title":"Front Pharmacol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2013.01.009","article-title":"Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease","volume":"7","author":"Mocci G","year":"2013","unstructured":"Mocci G, Marzo M, Papa A, Armuzzi A, Guidi L. Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease. J Crohns Colitis. 2013, 7:769-79. 10.1016\/j.crohns.2013.01.009","journal-title":"J Crohns Colitis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.15.4449","article-title":"Stevens-Johnson syndrome complicating adalimumab therapy in Crohn's disease","volume":"15","author":"Salama M","year":"2009","unstructured":"Salama M, Lawrance IC. Stevens-Johnson syndrome complicating adalimumab therapy in Crohn's disease. World J Gastroenterol. 2009, 15:4449-52. 10.3748\/wjg.15.4449","journal-title":"World J Gastroenterol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-017-8667-7","article-title":"Current perspectives on erythema multiforme","volume":"54","author":"Lerch M","year":"2018","unstructured":"Lerch M, Mainetti C, Terziroli Beretta-Piccoli B, Harr T. Current perspectives on erythema multiforme. Clin Rev Allergy Immunol. 2018, 54:177-84. 10.1007\/s12016-017-8667-7","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2011.05348.x","article-title":"Clinical features, diagnosis, and treatment of erythema multiforme: a review for the practicing dermatologist","volume":"51","author":"Sokumbi O","year":"2012","unstructured":"Sokumbi O, Wetter DA. Clinical features, diagnosis, and treatment of erythema multiforme: a review for the practicing dermatologist. Int J Dermatol. 2012, 51:889-902. 10.1111\/j.1365-4632.2011.05348.x","journal-title":"Int J Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.oooo.2012.08.001","article-title":"Erythema multiforme major following treatment with infliximab","volume":"115","author":"Edwards D","year":"2013","unstructured":"Edwards D, Boritz E, Cowen EW, Brown RS. Erythema multiforme major following treatment with infliximab. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013, 115:e36-40. 10.1016\/j.oooo.2012.08.001","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"ref9","doi-asserted-by":"crossref","DOI":"10.5070\/D3246040714","article-title":"Golimumab-associated persistent erythema multiforme in a patient with ulcerative colitis in full remission","volume":"24","author":"Badavanis G","year":"2018","unstructured":"Badavanis G, Pasmatzi E, Kapranos N, Monastirli A, Tsambaos D. Golimumab-associated persistent erythema multiforme in a patient with ulcerative colitis in full remission. Dermatol Online J. 2018, 24:13030\/qt4qr908k5.","journal-title":"Dermatol Online J"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.04.048","article-title":"Erythema multiforme during anti-tumor necrosis factor treatment for plaque psoriasis","volume":"62","author":"Ahdout J","year":"2010","unstructured":"Ahdout J, Haley JC, Chiu MW. Erythema multiforme during anti-tumor necrosis factor treatment for plaque psoriasis. J Am Acad Dermatol. 2010, 62:874-9. 10.1016\/j.jaad.2009.04.048","journal-title":"J Am Acad Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04682.x","article-title":"Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease","volume":"34","author":"Steenholdt C","year":"2011","unstructured":"Steenholdt C, Svenson M, Bendtzen K, Thomsen O\u00d8, Brynskov J, Ainsworth MA. Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2011, 34:51-8. 10.1111\/j.1365-2036.2011.04682.x","journal-title":"Aliment Pharmacol Ther"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2174\/1574886312666170518124014","article-title":"Biologic agents in systemic dermatotherapy: cutaneous and systemic side effects","volume":"Online ahead of print","author":"Badavanis G","year":"2017","unstructured":"Badavanis G, Pasmatzi E, Monastirli A, Tsambaos D. Biologic agents in systemic dermatotherapy: cutaneous and systemic side effects. Curr Drug Saf. 2017,  Online ahead of print:10.2174\/1574886312666170518124014","journal-title":"Curr Drug Saf"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/81979-adalimumab-induced-erythema-multiforme-in-a-patient-with-rheumatoid-arthritis-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:41:39Z","timestamp":1707507699000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/81979-adalimumab-induced-erythema-multiforme-in-a-patient-with-rheumatoid-arthritis-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,11]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.21126","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1,11]]}}}